Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

US7361654B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• James Sheppeck · Wilmington, US
• T. G. Murali Dhar · Newtown, US
• Lidia M. Doweyko · Vero Beach, US
• John L. Gilmore · Yardley, US
• David S. Weinstein · Plainsboro, US
• Hai-Yun Xiao · Montgomery, US
• Bingwei Yang · Montgomery, US
• Arthur M. P. Doweyko · Long Valley, US

Key dates

• Filing date: Jan 12, 2006
• Grant date: Apr 22, 2008
• Expiry date: Jan 12, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory- and immune-associated diseases, and have the structureincluding all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR6; Z is a ring; and where R, Ra, Rb, Rc, Rd, R1, R2, R3, R4, and R5 are as defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising such compounds.